{
    "clinical_study": {
        "@rank": "144697", 
        "arm_group": [
            {
                "arm_group_label": "Oxabact OC5 capsules", 
                "arm_group_type": "Experimental", 
                "description": "The active study drug consists of OC5 in enteric-coated size-4 capsules. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks."
            }, 
            {
                "arm_group_label": "Placebo capsules", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if Oxalobacter formigenes is effective at lowering\n      urinary oxalate levels in patients with primary hyperoxaluria."
        }, 
        "brief_title": "Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Hyperoxaluria", 
        "condition_browse": {
            "mesh_term": [
                "Hyperoxaluria", 
                "Hyperoxaluria, Primary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent (as applicable for the age of the subject).\n\n          -  Male or female subjects \u2265 2 years of age (Germany & France) / Male or female subjects\n             \u2265 5 years of age (United Kingdom)\n\n          -  A diagnosis of PH type I (as determined by standard diagnostic methods).\n\n          -  A mean urinary oxalate excretion of > 1.0 mmol/24h/1.73m2, based on at least three\n             eligible urine collections performed during baseline (weeks 1-4).\n\n          -  Renal function defined as an estimated GFR \u2265 40 ml/min normalised to 1.73m2 body\n             surface area, or a creatinine clearance of \u2265 40 ml/min normalised to 1.73m2 body\n             surface area.\n\n          -  Subjects receiving vitamin B6 must be receiving a stable dose for at least 3 months\n             prior to screening and must not change the dose during the study. Subjects not\n             receiving vitamin B6 at study entry must be willing to refrain from initiating\n             pyridoxine during study participation.\n\n        Exclusion Criteria:\n\n          -  Inability to collect complete 24-hour urine samples. Each urine collection will be\n             evaluated for completeness based on urine qualitative criteria.\n\n          -  Inability to swallow size 4 capsules twice daily for 8 to 10 weeks.\n\n          -  Subjects that have undergone transplantation (solid organ or bone marrow).\n\n          -  The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery\n             or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory\n             bowel disease and short-bowel syndrome.\n\n          -  Use of antibiotics to which O. formigenes is sensitive, including chronic use, a\n             history of more than two courses of antibiotic use during the past 6 months, current\n             antibiotic use, or antibiotics use within 14 days of initiating study medication.\n\n          -  Subjects who require immune suppressive therapy.\n\n          -  Current treatment with ascorbic acid preparation.\n\n          -  Pregnancy.\n\n          -  Women of child-bearing potential who are not using adequate contraceptive precautions\n             such as oral, transdermal, injectable, or implanted contraceptives, IUD, complete\n             abstinence, use of a condom by the sexual partner, or sterile sexual partner.\n\n          -  Presence of a medical condition that the Principal Investigator considers likely to\n             make the subject susceptible to adverse effect of study treatment or unable to follow\n             study procedures.\n\n          -  Participation in any study of an investigational product, biologic, device, or other\n             agent within 30 days prior to screening or not willing to forego other forms of\n             investigational treatment during this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012985", 
            "org_study_id": "OC5-DB-01"
        }, 
        "intervention": {
            "arm_group_label": "Oxabact OC5 capsules", 
            "description": "The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.", 
            "intervention_name": "Oxabact OC5 capsules", 
            "intervention_type": "Biological", 
            "other_name": "Oxalobacter formigenes"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hyperoxaluria", 
            "oxalate", 
            "PH"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33076"
                    }, 
                    "name": "H\u00f4pital des Enfants, Centre de r\u00e9f\u00e9rence maladies r\u00e9nales rares du Sud-Ouest (SORARE), CHU de Bordeaux"
                }, 
                "investigator": {
                    "last_name": "J\u00e9r\u00f4me Harambat, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69677 Bron"
                    }, 
                    "name": "H\u00f4pital Femme M\u00e8re Enfant, Lyon - Paediatric Dept"
                }, 
                "investigator": {
                    "last_name": "Pierre Cochat, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }, 
                    "name": "H\u00f4pital Necker-Enfants Malades,Centre de r\u00e9f\u00e9rence des Maladies R\u00e9nales H\u00e9r\u00e9ditaires de l'Enfant et de l'Adulte (MARHEA)"
                }, 
                "investigator": {
                    "last_name": "R\u00e9mi Salomon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "DE-53113"
                    }, 
                    "name": "Universit\u00e4tsklinikum Bonn, Dept of Paediatric Nephrology"
                }, 
                "investigator": {
                    "last_name": "Bernd Hoppe, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B4 6NH"
                    }, 
                    "name": "Birmingham Children's Hospital NHS Foundation Trust - Dept of Nephrology"
                }, 
                "investigator": {
                    "last_name": "Sally Hulton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2QG"
                    }, 
                    "name": "Royal Free Hospital -UCL Centre for Nephrology"
                }, 
                "investigator": {
                    "last_name": "Shabbir Moochhala, MCRP PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WCIN 3JH"
                    }, 
                    "name": "Great Ormond Street Hospital for Children NHS Trust"
                }, 
                "investigator": {
                    "last_name": "William van't Hoff, FRCP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria", 
        "overall_contact": {
            "email": "anna.sjogren@oxthera.com", 
            "last_name": "Anna Sj\u00f6gren", 
            "phone": "+46 8 660 0223"
        }, 
        "overall_contact_backup": {
            "email": "orla.mccallion@oxthera.com", 
            "last_name": "Orla N Mc Callion, BSc PhD", 
            "phone": "+46 8 660 0223"
        }, 
        "overall_official": {
            "affiliation": "Universit\u00e4tsklinikum Bonn, Dept of Paediatric Nephrology", 
            "last_name": "Bernd Hoppe, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in urinary oxalate levels from Baseline to week 8 of treatment.", 
            "safety_issue": "No", 
            "time_frame": "8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in urinary oxalate levels from Baseline to week 8 of treatment in subsets of subjects defined by:\nbaseline urinary oxalate level, above and below 1.5 mmol/24h/1.73m2\nconcomitant vitamin B6 therapy and no vitamin B6 therapy\neGFR of \u226590 mL/min/1.73m2 (normal renal function) and < 90 mL/min/1.73m2 (mild to moderate reduction in renal function)\nage below 18 and age 18 or above", 
                "measure": "Change in urinary oxalate levels from Baseline to week 8 of treatment in subsets of subjects", 
                "safety_issue": "No", 
                "time_frame": "8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)"
            }, 
            {
                "measure": "Number of subjects who reach urinary oxalate levels below 0.5, 0.7 and 1.0 mmol/24h/1.73m2 respectively from Baseline to week 8 of treatment.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)"
            }, 
            {
                "measure": "Change in plasma oxalate levels from Baseline to week 8 of treatment.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)"
            }, 
            {
                "measure": "Change in urinary oxalate levels from Baseline to week 4 of treatment.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks of active treatment (i.e. between Weeks 7 and 10 of the study)"
            }, 
            {
                "measure": "Correlation between change in plasma oxalate levels and change in urinary oxalate levels, from Baseline to week 8 of treatment.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)"
            }, 
            {
                "measure": "Change in number of O. formigenes in faeces from Baseline to week 8 of treatment.", 
                "safety_issue": "No", 
                "time_frame": "8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study)"
            }, 
            {
                "description": "Blood samples taken for hematology at weeks 0, 5, 10 and 14. Complete blood count with differential and platelet count evaluated.", 
                "measure": "Haematology", 
                "safety_issue": "Yes", 
                "time_frame": "14 weeks (Throughout the study)"
            }, 
            {
                "description": "Blood samples taken for clinical chemistry at weeks 0, 5, 10 and 14. Blood Urea Nitrogen, creatinine, electrolytes (Na+, K+, Mg++, Ca++, HCO3+, Cl), glucose, pH, albumin, alkaline phosphatase, ALT, AST, total bilirubin and total protein evaluated.", 
                "measure": "Clinical Chemistry", 
                "safety_issue": "Yes", 
                "time_frame": "14 weeks (Throughout the study)"
            }, 
            {
                "description": "Urine samples will be taken at weeks 0, 5, 10 and 14 of the study. Protein, glucose and pH evaluated.", 
                "measure": "Urinalysis", 
                "safety_issue": "Yes", 
                "time_frame": "14 weeks (Throughout the study)"
            }
        ], 
        "source": "OxThera", 
        "sponsors": {
            "collaborator": {
                "agency": "FP7-SME-2013 Research for the benefit of SMEs program", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "OxThera", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}